Boca Raton Regional Hospital is a 400-bed, not-for-profit health care organization located in Boca Raton, Florida. It was established in 1967 and provides patient care in areas such as cardiovascular, oncology, women's health, orthopedics, emergency medicine and the neurosciences. Presently, the hospital has 400 licensed beds, 800 physicians, a nursing and support staff of 2000 and 1200 volunteers.
Abstract Background Patients with unresectable IDH-wildtype rGBM have a paucity of available therapeutic options and a median overall survival (OS) of 5-7 months. Bizaxofusp (MDNA55) is an interleukin-4 receptor (IL4R)-targeted fusion protein designed to selectively deliver a cytotoxic payload to GBM cells and the immunosuppressive tumor microenvironment via convection-enhanced delivery (CED). Here we report survival outcomes from MDNA55-05 (NCT02858895) versus an ECA derived from patient-level data in the intended Phase 3 population. Methods MDNA55-05 was a multicenter Phase 2b study evaluating single-dose intratumoral bizaxofusp administered by MRI-guided CED in adults with unresectable rGBM following first or second relapse. Primary endpoint was OS from eligible relapse date to death or censoring; secondary endpoints included safety and tumor response. OS in the per-protocol (PP) population (N = 43) was compared with a contemporaneous ECA derived from patient registries of standard-of-care patients meeting key eligibility criteria. Additional analysis compared IDH-wildtype patients treated at the recommended Phase 3 dose (RP3D; ≥180 μg) (N = 19), including 12 MGMT-unmethylated tumors, with an IDH-wildtype ECA. Cohorts were balanced using propensity score weighting across 10 baseline prognostic variables, with acceptable balance after weighting. Results In the PP population (N = 43), bizaxofusp improved mOS versus matched ECA (12.5 vs 7.2 months; HR 0.621, 95% CI 0.413–0.934; p = 0.023). In IDH-wildtype patients at RP3D, mOS substantially improved versus matched ECA (13.7 vs 6.2 months; HR 0.499, 95% CI 0.278–0.895; p = 0.013). Twelve-month OS rates were 52.6% (95% CI 28.7–71.9) for bizaxofusp versus 15.6% (95% CI 6.5–28.4) for matched ECA. Bizaxofusp demonstrated a manageable safety profile; treatment-related adverse events primarily comprised neurological events associated with GBM and the CED procedure. Conclusions In patients with unresectable IDH-wildtype rGBM treated at RP3D, bizaxofusp markedly improved OS compared with a rigorously matched contemporary ECA. Survival benefit was observed without selection for IL4R expression, supporting registrational development.
We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety and efficacy of short-course bendamustine/rituximab (BR) induction followed by venetoclax/rituximab (VR) consolidation. In a multicenter, single-arm Phase 2 trial (NCT03609593), previously untreated CLL/SLL needing therapy received BR for three 28-day cycles followed by venetoclax ramp-up to 400 mg daily plus rituximab every 28 days for six cycles; venetoclax continued to 12 cycles (total treatment, 15 months). The primary endpoint was overall response rate (ORR); key secondary endpoints included uMRD, PFS/OS, and safety per CTCAE v4. Forty-two patients were enrolled (median age 61.5 years; 64% unmutated IGHV; 29% complex karyotype; 10% TP53 aberrancy); 93% completed all planned therapy. At end of treatment, ITT ORR was 86% (CR/CRi 64%, PR 21%); among efficacy-evaluable patients, ORR was 100% (CR/CRi 75%). End-of-therapy uMRD was achieved by 83% in bone marrow and 84% in blood among efficacy-evaluable patients. Three-year PFS and OS were 87.5% and 92.7%. TLS risk was downstaged after BR, and no TLS events occurred. Febrile neutropenia occurred in 12% of patients. Two on-study deaths due to COVID-19 occurred; no Richter transformation occurred. Time-limited BR-VR achieved high uMRD rates and durable remissions with a manageable safety profile. While the treatment landscape in CLL has largely shifted toward chemotherapy-free regimens, these data demonstrate the biological proof-of-concept that limited induction chemotherapy can effectively mitigate TLS risk and facilitate safe outpatient ramp-up of venetoclax.
BACKGROUND:Atrial fibrillation (AF) can lead to significant cardiovascular events and health care utilization. Continuous monitoring via insertable cardiac monitors (ICMs) and data analytics have the potential to improve care delivery. OBJECTIVE:The DEFINE Atrial Fibrillation (DEFINE AFib) study was designed to develop and evaluate novel algorithms using ICM data to predict AF-associated clinical actions (AFCAs) and guide AF management. METHODS:DEFINE AFib enrolled patients with an ICM (Reveal LINQ/LINQ II; Medtronic) and a history of AF. An Apple iPhone application collected AF-related quality of life (AFEQT) and EQ-5D data. ICM daily AF burden and Apple Watch (AW) irregular rhythm notification (IRN) data were also collected. AFCA was defined as an AF-related procedure or initiation of rate/rhythm control medication. Mutivariable logistic regression was used to identify ICM features in the last 30 days associated with first occurrence of AFCA in the next 30 days in a train and test approach (70%/30%). RESULTS:Among 864 patients (mean 69 ± 10 years; 56% male) meeting inclusion criteria, there were 8963 30-day evaluation windows that included 151 AFCAs. Area under the receiver operating characteristic curve (AUC) was 76% (train) and 70% (test). The model placed participants into high- vs low-risk AFCA groups. At the patient-level, 21% of participants crossing the high-risk threshold for their first time experienced an AFCA at a mean time of 195 ± 164 days compared with 5% in the low-risk group (AUC 65%). Increasing daily mean AF burden was associated with lower quality of life: <6 minutes (reference), 6 minutes to 5.5 hours (AFEQT -7.69; P < .001), and 5.5-12 hours (AFETQ -13.97, P < .001; ≥5.5 hours EQ-5D -0.03, P = .007). In a subanalysis of individuals with smart watch data (n = 53), the ICM model signaled high risk before AFCAs 85% of the time (AUC 57%) compared with 23% for AW IRN (P = .005; AUC 55%). CONCLUSION:DEFINE AFib transformed ICM diagnostic data to predict risk of AFCA with good discrimination, particularly compared with wearable data. These results highlight the potential advantages of ICM-based continuous monitoring for AF management and the utility of ICM prediction models that could help inform pre-emptive therapeutic strategies.